Johnson & Johnson (NYSE:JNJ) Shares Sold by International Private Wealth Advisors LLC

International Private Wealth Advisors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,516 shares of the company’s stock after selling 88 shares during the period. International Private Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $246,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in JNJ. Intelligence Driven Advisers LLC acquired a new stake in Johnson & Johnson in the third quarter valued at about $243,000. Tokio Marine Asset Management Co. Ltd. lifted its position in Johnson & Johnson by 5.4% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 66,313 shares of the company’s stock valued at $10,747,000 after purchasing an additional 3,392 shares during the period. Metis Global Partners LLC lifted its position in Johnson & Johnson by 3.2% in the third quarter. Metis Global Partners LLC now owns 138,758 shares of the company’s stock valued at $22,487,000 after purchasing an additional 4,283 shares during the period. Curi RMB Capital LLC lifted its position in Johnson & Johnson by 2.2% in the third quarter. Curi RMB Capital LLC now owns 104,083 shares of the company’s stock valued at $16,868,000 after purchasing an additional 2,239 shares during the period. Finally, Planning Capital Management Corp lifted its position in shares of Johnson & Johnson by 1.0% during the 3rd quarter. Planning Capital Management Corp now owns 30,124 shares of the company’s stock valued at $4,882,000 after acquiring an additional 309 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.9 %

JNJ stock opened at $151.86 on Friday. The stock has a market capitalization of $365.62 billion, a P/E ratio of 21.98, a PEG ratio of 2.72 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a 50 day moving average price of $161.82 and a two-hundred day moving average price of $155.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the business earned $2.66 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.27%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Citigroup lifted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, TD Securities reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $175.00.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.